Cargando…

Necrosis binding of Ac-Lys(0)(IRDye800CW)-Tyr(3)-octreotate: a consequence from cyanine-labeling of small molecules

BACKGROUND: There is a growing body of nuclear contrast agents that are repurposed for fluorescence-guided surgery. New contrast agents are obtained by substituting the radioactive tag with, or adding a fluorescent cyanine to the molecular structure of antibodies or peptides. This enables intra-oper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stroet, Marcus C. M., Dijkstra, Bianca M., Dulfer, Sebastiaan E., Kruijff, Schelto, den Dunnen, Wilfred F. A., Kruyt, Frank A. E., Groen, Rob J. M., Seimbille, Yann, Panth, Kranthi M., Mezzanotte, Laura, Lowik, Clemens W. G. M., de Jong, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110618/ https://www.ncbi.nlm.nih.gov/pubmed/33970376 http://dx.doi.org/10.1186/s13550-021-00789-4

Ejemplares similares

Evaluation of Ac-Lys(0)(IRDye800CW)Tyr(3)-octreotate as a novel tracer for SSTR(2)-targeted molecular fluorescence guided surgery in meningioma
por: Dijkstra, Bianca M., et al.
Publicado: (2021)

Correction to: Evaluation of Ac-Lys(0)(IRDye800CW)Tyr(3)-octreotate as a novel tracer for SSTR(2)-targeted molecular fluorescence guided surgery in meningioma
por: Dijkstra, Bianca M., et al.
Publicado: (2021)

Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain
por: Stroet, Marcus C. M., et al.
Publicado: (2022)

In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors
por: Stroet, Marcus C. M., et al.
Publicado: (2021)

In Vivo Evaluation of Indium-111–Labeled 800CW as a Necrosis-Avid Contrast Agent
por: Stroet, Marcus C. M., et al.
Publicado: (2020)

Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018)

Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW
por: Amini, Abolfazl, et al.
Publicado: (2022)

Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats
por: Marshall, Milton V., et al.
Publicado: (2010)

Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
por: Bernhard, Wendy, et al.
Publicado: (2021)

Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW
por: Krishnan, Giri, et al.
Publicado: (2021)

Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma
por: Wellens, Lianne M., et al.
Publicado: (2020)

Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets
por: Cohen, Ruth, et al.
Publicado: (2011)

Near infrared fluorescence imaging of EGFR expression in vivo using IRDye800CW-nimotuzumab
por: Bernhard, Wendy, et al.
Publicado: (2017)

Detection of Tumour-Targeted IRDye800CW Tracer with Commercially Available Laparoscopic Surgical Systems
por: Sikkenk, Daan J., et al.
Publicado: (2023)

Targeted Optical Imaging of the Glucagonlike Peptide 1 Receptor Using Exendin-4-IRDye 800CW
por: Boss, Marti, et al.
Publicado: (2020)

The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma
por: Youn, Gun Min, et al.
Publicado: (2022)

Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab(®)-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery
por: Polikarpov, Dmitry M., et al.
Publicado: (2020)

Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node
por: Heuveling, Derrek A., et al.
Publicado: (2012)

Tumor-Specific Imaging with Angiostamp800 or Bevacizumab-IRDye 800CW Improves Fluorescence-Guided Surgery over Indocyanine Green in Peritoneal Carcinomatosis
por: Josserand, Véronique, et al.
Publicado: (2022)

Manufacture of IRDye800CW-coupled Fe(3)O(4 )nanoparticles and their applications in cell labeling and in vivo imaging
por: Hou, Yong, et al.
Publicado: (2010)

A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies
por: Oliveira, Sabrina, et al.
Publicado: (2012)

IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
por: Kurbegovic, Sorel, et al.
Publicado: (2021)

First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using (68)Ga-IRDye800CW-BBN
por: Li, Deling, et al.
Publicado: (2018)

Towards Photodynamic Image-Guided Surgery of Head and Neck Tumors: Photodynamic Priming Improves Delivery and Diagnostic Accuracy of Cetuximab-IRDye800CW
por: Bhandari, Chanda, et al.
Publicado: (2022)

Preclinical assessment of IRDye800CW‐labeled gastrin‐releasing peptide receptor‐targeting peptide for near infrared‐II imaging of brain malignancies
por: Zhang, Yuan, et al.
Publicado: (2023)

Multimodal image-guided surgery of HER2-positive breast cancer using [(111)In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model
por: Deken, Marion M., et al.
Publicado: (2019)

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with (89)Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
por: ter Weele, Eva J., et al.
Publicado: (2015)

Fluorescence-guided craniotomy of glioblastoma using panitumumab-IRDye800
por: Zhou, Quan, et al.
Publicado: (2022)

Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate
por: Ma, Michelle T., et al.
Publicado: (2015)

Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model
por: Du, Yang, et al.
Publicado: (2017)

Effects of therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate on endocrine function
por: Teunissen, Jaap J. M., et al.
Publicado: (2009)

First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800
por: Miller, Sarah E., et al.
Publicado: (2018)

Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial
por: Vergeer, Rob A, et al.
Publicado: (2021)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009)

Validation of Quality Control Parameters of Cassette-Based Gallium-68-DOTA-Tyr3-Octreotate Synthesis
por: Sammartano, Antonino, et al.
Publicado: (2020)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial
por: Zhou, Quan, et al.
Publicado: (2021)

Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
por: He, Kunshan, et al.
Publicado: (2020)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l06a9ak1qghigcq5qefn3f01nd